Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

NCT05683964 · clinicaltrials.gov ↗

EARLY_PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

9

Enrollment

OTHER

Sponsor class

Conditions

Prostate Adenocarcinoma
Prostate Cancer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)

Interventions

DRUG: Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi]
DIAGNOSTIC_TEST: Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan

Sponsor

Beth Israel Deaconess Medical Center

Collaborators

[object Object]